SG Americas Securities LLC Has $5.17 Million Position in Certara, Inc. $CERT

Posted by Brenda Bartman on Jun 29th, 2026

SG Americas Securities LLC increased its holdings in shares of Certara, Inc. (NASDAQ:CERT – Free Report) by 1,717.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 906,615 shares of the company’s stock after purchasing an additional 856,729 shares during the period. SG Americas Securities LLC’s holdings in Certara were worth $5,168,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of CERT. Northwestern Mutual Wealth Management Co. increased its stake in Certara by 2,733.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock worth $26,000 after purchasing an additional 2,870 shares in the last quarter. Osaic Holdings Inc. lifted its stake in Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Certara by 499.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock valued at $69,000 after buying an additional 4,930 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of Certara in the second quarter valued at approximately $83,000. Finally, Curated Wealth Partners LLC acquired a new position in shares of Certara in the fourth quarter valued at approximately $89,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Stock Performance

Shares of CERT stock opened at $5.83 on Monday. Certara, Inc. has a 12 month low of $4.45 and a 12 month high of $13.88. The company’s fifty day simple moving average is $5.58 and its 200-day simple moving average is $6.92. The firm has a market cap of $906.20 million, a PE ratio of -58.25 and a beta of 1.49. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT – Get Free Report) last released its earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The business had revenue of $106.92 million during the quarter, compared to the consensus estimate of $106.13 million. During the same period last year, the business posted $0.14 EPS. The firm’s revenue for the quarter was up .8% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Equities research analysts expect that Certara, Inc. will post 0.24 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on CERT shares. BMO Capital Markets dropped their price objective on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Tuesday, May 12th. Morgan Stanley reduced their target price on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Craig Hallum lowered their target price on Certara from $10.00 to $8.00 and set a “hold” rating for the company in a report on Tuesday, May 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Certara in a research note on Friday, May 29th. Finally, Robert W. Baird cut their price target on Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Certara presently has an average rating of “Hold” and an average target price of $8.85.

Read Our Latest Stock Report on CERT

Certara Profile

(Free Report)

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.